V114-005 A Phase l-ll, randomized, Double-Blind, Study to Evaluate the safety, Tolerability, and Immunogenicity of Different formulations of V114 in Healthy Adults and Infants

Project: Other project

StatusFinished
Effective start/end date8/18/158/17/18

Funding

  • Merck Sharp & Dohme Corporation: $95,379.69